MetLife Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $227K | Hold |
15,542
| – | – | ﹤0.01% | 2357 |
|
|
2026
Q1 | $196K | Buy |
15,542
+1,134
| +8% | +$15.2K | ﹤0.01% | 2240 |
|
|
2025
Q4 | $227K | Buy |
14,408
+7,849
| +120% | +$99.7K | ﹤0.01% | 2207 |
|
|
2025
Q3 | $78.5K | Sell |
6,559
-6,456
| -50% | -$51.6K | ﹤0.01% | 2737 |
|
|
2025
Q2 | $98.4K | Sell |
13,015
-64
| -0.5% | -$385 | ﹤0.01% | 2546 |
|
|
2025
Q1 | $72.2K | Buy |
+13,079
| New | +$80.8K | ﹤0.01% | 2637 |
|
|
2024
Q4 | – | Sell |
-11,454
| Closed | -$119K | – | 2826 |
|
|
2024
Q3 | $119K | Hold |
11,454
| – | – | ﹤0.01% | 2561 |
|
|
2024
Q2 | $149K | Buy |
11,454
+1,114
| +11% | +$15K | ﹤0.01% | 2416 |
|
|
2024
Q1 | $181K | Hold |
10,340
| – | – | ﹤0.01% | 2252 |
|
|
2023
Q4 | $97.3K | Hold |
10,340
| – | – | ﹤0.01% | 2619 |
|
|
2023
Q3 | $115K | Hold |
10,340
| – | – | ﹤0.01% | 2506 |
|
|
2023
Q2 | $221K | Hold |
10,340
| – | – | ﹤0.01% | 2209 |
|
|
2023
Q1 | $418K | Hold |
10,340
| – | – | ﹤0.01% | 1753 |
|
|
2022
Q4 | $481K | Hold |
10,340
| – | – | ﹤0.01% | 1671 |
|
|
2022
Q3 | $536K | Sell |
10,340
-619
| -6% | -$36.2K | ﹤0.01% | 1589 |
|
|
2022
Q2 | $518K | Hold |
10,959
| – | – | ﹤0.01% | 1639 |
|
|
2022
Q1 | $780K | Buy |
10,959
+4,139
| +61% | +$269K | 0.01% | 1485 |
|
|
2021
Q4 | $510K | Hold |
6,820
| – | – | ﹤0.01% | 1500 |
|
|
2021
Q3 | $387K | Sell |
6,820
-1,474
| -18% | -$72.9K | ﹤0.01% | 1671 |
|
|
2021
Q2 | $365K | Hold |
8,294
| – | – | ﹤0.01% | 1764 |
|
|
2021
Q1 | $409K | Hold |
8,294
| – | – | ﹤0.01% | 1644 |
|
|
2020
Q4 | $349K | Hold |
8,294
| – | – | ﹤0.01% | 1674 |
|
|
2020
Q3 | $380K | Hold |
8,294
| – | – | ﹤0.01% | 1514 |
|
|
2020
Q2 | $416K | Hold |
8,294
| – | – | ﹤0.01% | 1485 |
|
|
2020
Q1 | $427K | Buy |
8,294
+696
| +9% | +$37.1K | 0.01% | 1298 |
|
|
2019
Q4 | $469K | Hold |
7,598
| – | – | ﹤0.01% | 1500 |
|
|
2019
Q3 | $456K | Hold |
7,598
| – | – | 0.01% | 1466 |
|
|
2019
Q2 | $641K | Sell |
7,598
-15,196
| -67% | -$1.37M | 0.01% | 1340 |
|
|
2019
Q1 | $2.18M | Buy |
22,794
+15,196
| +200% | +$1.36M | 0.01% | 1202 |
|
|
2018
Q4 | $538K | Hold |
7,598
| – | – | 0.01% | 1328 |
|
|
2018
Q3 | $649K | Hold |
7,598
| – | – | 0.01% | 1364 |
|
|
2018
Q2 | $881K | Hold |
7,598
| – | – | 0.01% | 1076 |
|
|
2018
Q1 | $615K | Hold |
7,598
| – | – | 0.01% | 1248 |
|
|
2017
Q4 | $446K | Buy |
+7,598
| New | +$380K | 0.01% | 1464 |
|
Other funds holding ENTA
JT
KAM
FCM
DTC
ACM
SSC
MetLife Investment Management's ENTA Position: Q2 2026 in Review
MetLife Investment Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 15,542 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #2357.
MetLife Investment Management first reported a position in ENTA in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.18M in Q1 2019. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- MetLife Investment Management held 15,542 shares of Enanta Pharmaceuticals worth $227K as of Q2 2026.
- MetLife Investment Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
- Enanta Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2357 holding.
- MetLife Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Enanta Pharmaceuticals position peaked at $2.18M in Q1 2019.
- 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.